S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

AbbVie and Galderma Dominate 80% of Aesthetic Medicine AI Citations

Two pharmaceutical giants, AbbVie and Galderma, effectively dictate the digital patient pipeline in the $25 billion aesthetic medicine industry. According to the 2026 AI Visibility Index, these companies secure 80% of all AI-generated citations, leaving thousands of independent medical spas to compete for a mere 5% of search visibility.

AbbVie and Galderma Dominate 80% of Aesthetic Medicine AI Citations
Photo: Bio & News

The report, issued by 5W AI Communications, analyzed how major AI engines like ChatGPT, Claude, and Google AI Overviews route potential patients to providers. The findings reveal a stark consolidation of market influence, where AbbVie/Allergan leads with 47% of citation share, followed by Galderma at 33%. Smaller competitors Merz Aesthetics and Revance manage to capture the remainder of the top-tier visibility.

This concentration of influence creates a significant "Visibility Gap" for the roughly 12,000 facilities operating nationwide. While individual brands like Botox maintain near-total dominance—scoring 95 out of 100—independent med spas and even large chains like LaserAway struggle to gain traction against pharmaceutical marketing power. The data underscores a shift in consumer behavior where AI-driven answers serve as the primary gatekeeper for medical consultations, often excluding local providers before a patient makes a single inquiry.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!